$BIOCQ
Biocept Inc

2017 Form 10-K Financial Statement

#000156459018006985 Filed on March 28, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2016 Q3
Revenue $5.070M $1.292M $1.047M
YoY Change 57.3% 491.7% 535.27%
Cost Of Revenue $9.350M $1.899M $1.876M
YoY Change 35.11% 48.9% 61.79%
Gross Profit -$4.280M -$607.9K -$829.0K
YoY Change 15.77% -42.51% -16.67%
Gross Profit Margin -84.42% -47.06% -79.16%
Selling, General & Admin $13.53M $2.816M $3.197M
YoY Change 16.49% 5.53% 19.01%
% of Gross Profit
Research & Development $3.360M $668.4K $600.6K
YoY Change 23.83% -14.79% -11.38%
% of Gross Profit
Depreciation & Amortization $580.0K $70.00K $90.00K
YoY Change 80.12% 0.0% 12.5%
% of Gross Profit
Operating Expenses $16.89M $3.485M $3.798M
YoY Change 17.88% 0.91% 12.89%
Operating Profit -$21.17M -$4.092M -$4.627M
YoY Change 17.45% -9.27% 6.14%
Interest Expense -$480.0K -$130.0K $154.9K
YoY Change -191.28% -13.33% -186.04%
% of Operating Profit
Other Income/Expense, Net -$431.4K $40.00K -$116.5K
YoY Change 15.9% 0.0% -391.14%
Pretax Income -$21.61M -$4.190M -$4.743M
YoY Change 17.44% -9.31% 5.4%
Income Tax $7.624K $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.61M -$4.187M -$4.743M
YoY Change 17.47% -9.33% 5.49%
Net Earnings / Revenue -426.31% -324.17% -452.89%
Basic Earnings Per Share -$0.79 -$0.27 -$0.57
Diluted Earnings Per Share -$0.79 -$0.27 -$0.57
COMMON SHARES
Basic Shares Outstanding 27.25M 15.62M 8.371M
Diluted Shares Outstanding 27.25M 15.62M 8.371M

Balance Sheet

Concept 2017 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.150M $4.610M $680.0K
YoY Change -53.36% -47.73% -94.58%
Cash & Equivalents $678.9K
Short-Term Investments
Other Short-Term Assets $420.0K $480.0K $500.0K
YoY Change -12.5% 9.09% 8.7%
Inventory $500.0K $549.0K $497.5K
Prepaid Expenses
Receivables $1.190M $129.0K $85.66K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.260M $5.772M $1.761M
YoY Change -26.17% -40.12% -86.8%
LONG-TERM ASSETS
Property, Plant & Equipment $3.120M $1.806M $1.521M
YoY Change 72.38% 90.14% 76.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.120M $1.808M $1.521M
YoY Change 72.38% 90.94% 77.65%
TOTAL ASSETS
Total Short-Term Assets $4.260M $5.772M $1.761M
Total Long-Term Assets $3.120M $1.808M $1.521M
Total Assets $7.380M $7.580M $3.283M
YoY Change -2.64% -28.4% -76.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.270M $960.0K $1.700M
YoY Change 32.29% 51.77% 120.78%
Accrued Expenses $1.750M $1.160M $1.140M
YoY Change 50.86% 19.97% 23.91%
Deferred Revenue
YoY Change
Short-Term Debt $60.00K $80.00K $50.00K
YoY Change -25.0% 100.0%
Long-Term Debt Due $1.580M $2.200M $2.150M
YoY Change -28.18% 29.41% 27.98%
Total Short-Term Liabilities $4.660M $4.394M $5.050M
YoY Change 6.15% 31.51% 48.97%
LONG-TERM LIABILITIES
Long-Term Debt $1.150M $1.900M $2.170M
YoY Change -39.47% -35.15% -33.44%
Other Long-Term Liabilities $270.0K $620.0K $630.0K
YoY Change -56.45% 0.0% 3.28%
Total Long-Term Liabilities $1.420M $2.526M $2.793M
YoY Change -43.65% -28.91% -27.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.660M $4.394M $5.050M
Total Long-Term Liabilities $1.420M $2.526M $2.793M
Total Liabilities $6.080M $6.920M $7.839M
YoY Change -12.14% 0.37% 7.82%
SHAREHOLDERS EQUITY
Retained Earnings -$173.6M -$169.4M
YoY Change 11.85%
Common Stock $174.3M $164.9M
YoY Change 9.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.300M $658.7K -$4.556M
YoY Change
Total Liabilities & Shareholders Equity $7.380M $7.578M $3.283M
YoY Change -2.64% -28.42% -76.88%

Cashflow Statement

Concept 2017 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$21.61M -$4.187M -$4.743M
YoY Change 17.47% -9.33% 5.49%
Depreciation, Depletion And Amortization $580.0K $70.00K $90.00K
YoY Change 80.12% 0.0% 12.5%
Cash From Operating Activities -$19.65M -$4.440M -$2.970M
YoY Change 25.16% 4.47% -20.16%
INVESTING ACTIVITIES
Capital Expenditures $1.400M -$90.00K -$70.00K
YoY Change 190.45% 80.0% 40.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $30.00K
YoY Change -100.0%
Cash From Investing Activities -$1.400M -$60.00K -$70.00K
YoY Change 211.15% 20.0% 40.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.59M 8.430M -40.00K
YoY Change 55.68% 1328.81% -82.61%
NET CHANGE
Cash From Operating Activities -19.65M -4.440M -2.970M
Cash From Investing Activities -1.400M -60.00K -70.00K
Cash From Financing Activities 18.59M 8.430M -40.00K
Net Change In Cash -2.463M 3.930M -3.080M
YoY Change -41.5% -205.93% -23.0%
FREE CASH FLOW
Cash From Operating Activities -$19.65M -$4.440M -$2.970M
Capital Expenditures $1.400M -$90.00K -$70.00K
Free Cash Flow -$21.05M -$4.350M -$2.900M
YoY Change 30.09% 3.57% -20.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Cash
Cash
4609332
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1400180
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-372232
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18397269
CY2016 us-gaap Interest Expense
InterestExpense
525880
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
196542123
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17499397
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35183743
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17499397
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35183743
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-18399322
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7189529
CY2016 us-gaap Other Income
OtherIncome
153648
CY2017 us-gaap Other Income
OtherIncome
51216
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-431407
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21606113
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2053
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7624
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-21613737
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9578285
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27246292
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9578285
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27246292
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.92
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.92
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
3692735
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1593947
CY2016 bioc Stock Issued During Period Value Pursuant To Stock Purchase Agreement Net Of Issuance Costs
StockIssuedDuringPeriodValuePursuantToStockPurchaseAgreementNetOfIssuanceCosts
465293
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1247481
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7498535
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
575717
CY2017 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
50532
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1247481
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
45788
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
30662
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1064457
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-100875
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-518863
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
349932
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
236927
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
78649
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-76232
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19650726
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
30662
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1400180
CY2017 bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
13505094
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7498535
CY2017 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
150848
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
86227
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
166348
CY2016 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
510123
CY2017 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
465279
CY2016 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1238487
CY2017 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1934665
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11936464
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
18588185
CY2016 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-4211997
CY2017 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-2462721
CY2015Q4 us-gaap Cash
Cash
8821329
CY2016 us-gaap Interest Paid Net
InterestPaidNet
358632
CY2017 us-gaap Interest Paid Net
InterestPaidNet
358471
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2053
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5273
CY2016 bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
547000
CY2017 bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
451000
CY2016 us-gaap Financial Guarantee Insurance Contracts Premium Receivable Proceeds From Premiums Received
FinancialGuaranteeInsuranceContractsPremiumReceivableProceedsFromPremiumsReceived
3933
CY2016 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
975000
CY2017 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
719000
CY2016 bioc Aggregate Net Book Value Of Fixed Assets
AggregateNetBookValueOfFixedAssets
270000
CY2017 bioc Aggregate Net Book Value Of Fixed Assets
AggregateNetBookValueOfFixedAssets
34000
CY2016 bioc Equipment Financings Obligations With Remaining Outstanding Balances
EquipmentFinancingsObligationsWithRemainingOutstandingBalances
240000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
58000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000
CY2016Q2 bioc Issuance Of Unregistered Warrants To Purchase Common Stock Shares
IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares
1163526
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.90
CY2016Q2 bioc Class Of Warrant Or Right Expiry Period
ClassOfWarrantOrRightExpiryPeriod
P5Y
CY2016Q2 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
2000000
CY2016Q2 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
653000
CY2016Q4 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
0.57
CY2016Q4 bioc Underwriter Common Stock Grants Period
UnderwriterCommonStockGrantsPeriod
P30D
CY2016Q4 bioc Shares Issued To Underwriters Under Over Allotment Options Per Share
SharesIssuedToUnderwritersUnderOverAllotmentOptionsPerShare
1.0331
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0009
CY2016Q4 bioc Shares Issued To Underwriters Under Over Allotment Options Grant Date Fair Value
SharesIssuedToUnderwritersUnderOverAllotmentOptionsGrantDateFairValue
800000
CY2016Q4 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
1037000000000
CY2017Q3 bioc Issuance Of Unregistered Warrants To Purchase Common Stock Shares
IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares
1434639
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2017Q3 bioc Class Of Warrant Or Right Expiry Period
ClassOfWarrantOrRightExpiryPeriod
P5Y
CY2017Q3 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
1500000
CY2017Q1 bioc Issuance Of Unregistered Warrants To Purchase Common Stock Shares
IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares
2160000
CY2017Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.50
CY2017Q1 bioc Class Of Warrant Or Right Expiry Period
ClassOfWarrantOrRightExpiryPeriod
P5Y
CY2017Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
2800000
CY2017Q1 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
728000
CY2017Q3 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
176000
CY2017Q4 bioc Issuance Of Unregistered Warrants To Purchase Common Stock Shares
IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares
246250
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.85
CY2017Q4 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2018-06-05
CY2017Q4 bioc Class Of Warrant Or Right Expiry Period
ClassOfWarrantOrRightExpiryPeriod
P5Y
CY2017Q4 bioc Class Of Warrants Or Rights Expiration Date
ClassOfWarrantsOrRightsExpirationDate
2022-12-05
CY2017Q4 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
100000
CY2017Q4 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
428000
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and Business Activities </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company&#8217;s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company&#8217;s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient&#8217;s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company&#8217;s pathology partnership program, Empower TC, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, the Company&#8217;s proprietary blood collection tubes, which allow for the intact transport of liquid biopsy samples for research use only from regions around the world, are anticipated to be sold to laboratory supply distributors commencing in 2018.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company&#8217;s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July&#160;23, 2013.</p></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to accounts receivable, inventories, long-lived assets, income taxes, revenues, stock-based compensation, and the determination of the Company&#8217;s ability to continue as a going concern. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company&#8217;s services such as Medicare, insurance companies, and other third-party payers. The Company&#8217;s client base consists of a large number of geographically dispersed clients diversified across various customer types.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the years ended December 31, 2016 and 2017 were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.96%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.96%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.96%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.96%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2017 were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable business segment and historically has derived most revenues only from within the United States.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain components used in the Company&#8217;s current or planned products are currently sourced from one supplier, for which alternative suppliers exist but the Company has not validated the product(s) of such alternative supplier(s), and substitutes for these components may not be obtained easily or may require substantial design or manufacturing modifications. </p></div>
CY2016 bioc Development Services Revenues Recognized Upon Delivery Gross
DevelopmentServicesRevenuesRecognizedUponDeliveryGross
240056
CY2017 bioc Development Services Revenues Recognized Upon Delivery Gross
DevelopmentServicesRevenuesRecognizedUponDeliveryGross
272350
CY2016 bioc Commercial Revenues Recognized Upon Cash Collection Gross
CommercialRevenuesRecognizedUponCashCollectionGross
2983040
CY2017 bioc Commercial Revenues Recognized Upon Cash Collection Gross
CommercialRevenuesRecognizedUponCashCollectionGross
1225976
CY2016 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
3223096
CY2017 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
17183395
CY2017 bioc Provisions For Contractual Discounts
ProvisionsForContractualDiscounts
5805787
CY2017 bioc Provisions For Aged Non Patient Receivables
ProvisionsForAgedNonPatientReceivables
735709
CY2017 bioc Provisions For Estimated Patient Receivables
ProvisionsForEstimatedPatientReceivables
169479
CY2017Q4 bioc Aggregate Net Interest Bearing Indebtedness
AggregateNetInterestBearingIndebtedness
3100000
CY2017Q4 bioc Aggregate Net Interest Bearing Indebtedness Due Within One Year
AggregateNetInterestBearingIndebtednessDueWithinOneYear
2000000
CY2017Q4 bioc Other Non Interest Bearing Current Liabilities
OtherNonInterestBearingCurrentLiabilities
2700000
CY2016Q1 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
1062500
CY2017 bioc Unconditional Purchase Commitment Frequency Of Periodic Payment
UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment
Quarterly
CY2017 us-gaap Unrecorded Unconditional Purchase Obligation Date
UnrecordedUnconditionalPurchaseObligationDate
2020-05-31
CY2016Q4 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
9000000
CY2016Q4 bioc Shares Issued To Underwriters Under Over Allotment Options
SharesIssuedToUnderwritersUnderOverAllotmentOptions
627131
CY2016Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
564
CY2017 bioc Proceeds From Gross Warrant Exercises Outstanding
ProceedsFromGrossWarrantExercisesOutstanding
3200000
CY2017 bioc Warrants Exercisable Exercise Price Per Share
WarrantsExercisableExercisePricePerShare
1.10
CY2017 bioc Warrants Exercisable Exercise Price Per Share Expiration Period
WarrantsExercisableExercisePricePerShareExpirationPeriod
2021-10
CY2017Q3 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
2000000
CY2017Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2200000
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2017Q3 bioc Warrants Exercisable Exercise Price Per Share Expiration Period
WarrantsExercisableExercisePricePerShareExpirationPeriod
2022-08
CY2016Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.33
CY2017 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected on September 29, 2016.
CY2017 bioc Commercial Revenues Recognized Upon Delivery Gross
CommercialRevenuesRecognizedUponDeliveryGross
15685069
CY2017 bioc Provisions For Other Payer Specific Sales Allowances
ProvisionsForOtherPayerSpecificSalesAllowances
5403757
CY2017 bioc Nonrecurring Net Revenue Recognized On Accrual Basis Associated With Cases Delivered
NonrecurringNetRevenueRecognizedOnAccrualBasisAssociatedWithCasesDelivered
843000
CY2017 bioc Increase Decrease In Net Income Loss Per Common Share On Nonrecurring Net Revenue
IncreaseDecreaseInNetIncomeLossPerCommonShareOnNonrecurringNetRevenue
0.03
CY2017 bioc Net Revenue Recorded In Excess Of Commercial Cash Collections
NetRevenueRecordedInExcessOfCommercialCashCollections
1139000
CY2017 bioc Increase Decrease In Net Income Loss Per Common Share
IncreaseDecreaseInNetIncomeLossPerCommonShare
0.04
CY2016Q4 bioc Gross And Net Accounts Receivable
GrossAndNetAccountsReceivable
128969
CY2017 bioc Gross And Net Accounts Receivable For Amounts Recognized Upon Delivery
GrossAndNetAccountsReceivableForAmountsRecognizedUponDelivery
3842687
CY2017 bioc Gross And Net Accounts Receivable For Settlements Upon Adjudication
GrossAndNetAccountsReceivableForSettlementsUponAdjudication
-2778230
CY2017Q4 bioc Gross And Net Accounts Receivable
GrossAndNetAccountsReceivable
1193426
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2017 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
one supplier
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2017 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
42000
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
79000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1400000
CY2015Q2 bioc Shelf Registration Statement Expiration Period
ShelfRegistrationStatementExpirationPeriod
2018-05
CY2016Q4 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
5200000
CY2016Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2728468
CY2017Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2841388
CY2016Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
143726
CY2017Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
147976
CY2016Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
620582
CY2017Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
1637034
CY2016Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
517968
CY2017Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
553529
CY2016Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
1559690
CY2017Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
2294762
CY2016Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
169896
CY2017Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2975
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5740330
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7477664
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3933999
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4354097
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
20776
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
326602
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
168727
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
224813
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
364953
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
474953
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
422868
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
375000
CY2016Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
77844
CY2017Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
104509
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
67085
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
116681
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
37783
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
129805
CY2016 us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
77000
CY2016 bioc Cash Proceeds From Sale Of Fixed Assets
CashProceedsFromSaleOfFixedAssets
31000
CY2016Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
525000
CY2017Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
759000
CY2016 bioc Equipment Financings With Remaining Outstanding Balances
EquipmentFinancingsWithRemainingOutstandingBalances
240000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
438737
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
460166
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
406868
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
302229
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
268018
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
253951
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
2129969
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
570914
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
1559055
CY2017Q4 bioc Capital Leases Maintenance Obligation Payments Due Current
CapitalLeasesMaintenanceObligationPaymentsDueCurrent
63602
CY2017Q4 bioc Capital Leases Maintenance Obligation Payments Due In Two Years
CapitalLeasesMaintenanceObligationPaymentsDueInTwoYears
67394
CY2017Q4 bioc Capital Leases Maintenance Obligation Payments Due In Three Years
CapitalLeasesMaintenanceObligationPaymentsDueInThreeYears
55205
CY2017Q4 bioc Capital Leases Maintenance Obligation Payments Due In Four Years
CapitalLeasesMaintenanceObligationPaymentsDueInFourYears
44281
CY2017Q4 bioc Capital Leases Maintenance Obligation Payments Due In Five Years
CapitalLeasesMaintenanceObligationPaymentsDueInFiveYears
38479
CY2017Q4 bioc Capital Leases Maintenance Obligation Payments Due Thereafter
CapitalLeasesMaintenanceObligationPaymentsDueThereafter
39881
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
713659
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
290399
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
107396
CY2017Q4 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.51
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
896662
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1755031
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
202409
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2449284
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1774268
CY2017 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
-18026
CY2016 bioc Income Tax Reconciliation Section Three Eight Two Limitation
IncomeTaxReconciliationSectionThreeEightTwoLimitation
9256295
CY2017Q4 bioc Capital Leases Maintenance Obligation Payments Due
CapitalLeasesMaintenanceObligationPaymentsDue
308842
CY2017Q4 bioc Capital Leases Maintenance Obligation Payments Net
CapitalLeasesMaintenanceObligationPaymentsNet
308842
CY2016 bioc Equipment Financings Aggregate Weighted Average Interest Rate
EquipmentFinancingsAggregateWeightedAverageInterestRate
0.1318
CY2017 bioc Equipment Financings Aggregate Weighted Average Interest Rate
EquipmentFinancingsAggregateWeightedAverageInterestRate
0.1351
CY2017 bioc Equipment Financings Maturity Date Range Start
EquipmentFinancingsMaturityDateRangeStart
2018-06
CY2017 bioc Equipment Financings Maturity Date Range End
EquipmentFinancingsMaturityDateRangeEnd
2024-09
CY2017Q4 bioc Equipment Financings Minimum Payments Present Value Due Within One Year
EquipmentFinancingsMinimumPaymentsPresentValueDueWithinOneYear
409000
CY2017 bioc Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans
2
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
90000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 bioc Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Decrease In Net Deferred Tax Assets
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDecreaseInNetDeferredTaxAssets
2600000
CY2017 bioc Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2053
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7624
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2053
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
7624
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.03
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6255072
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7346079
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
2621803
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-260835
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.99
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.80
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.49
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.77
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.79
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.67
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12695397
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11458729
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-411853
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
67151
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
214313
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
157250
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
72696
CY2016 bioc Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
21548
CY2017 bioc Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
15568
CY2017 bioc Income Tax Reconciliation Expiration Of Net Operating Losses
IncomeTaxReconciliationExpirationOfNetOperatingLosses
922307
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
170950
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
200379
CY2016 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
44421
CY2017 bioc Income Tax Reconciliation Section Three Eight Two Limitation
IncomeTaxReconciliationSectionThreeEightTwoLimitation
1491942
CY2017 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
365263
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
96406
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
488264
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2954161
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1791805
CY2016 bioc Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
0.50
CY2017 bioc Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
0.50
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2218618
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3355180
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2244047
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2686666
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2273838
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2560417
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
164821
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
90866
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
-4556158
CY2016Q1 us-gaap Revenues
Revenues
221369
CY2016Q2 us-gaap Revenues
Revenues
662860
CY2016Q3 us-gaap Revenues
Revenues
1047280
CY2016Q4 us-gaap Revenues
Revenues
1291587
CY2016Q1 us-gaap Cost Of Revenue
CostOfRevenue
1474790
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
1669571
CY2016Q3 us-gaap Cost Of Revenue
CostOfRevenue
1876288
CY2016Q4 us-gaap Cost Of Revenue
CostOfRevenue
1899462
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
728076
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6901324
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8693129
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6901324
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8693129
CY2017Q4 bioc Percentage Of Change In Ownership
PercentageOfChangeInOwnership
0.50
CY2017 bioc Period Of Change In Ownership
PeriodOfChangeInOwnership
P3Y
CY2016Q4 bioc Number Of Consultants
NumberOfConsultants
1
CY2017 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-07-31
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1272000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1272000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1388705
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1430366
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
855136
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3674207
CY2016 bioc Capital Leases Sales Tax And Maintenance Obligations Expense
CapitalLeasesSalesTaxAndMaintenanceObligationsExpense
32000
CY2017 bioc Capital Leases Sales Tax And Maintenance Obligations Expense
CapitalLeasesSalesTaxAndMaintenanceObligationsExpense
79000
CY2017Q4 bioc Capital Leases Maintenance And Sales Tax Obligation Payments Due Current
CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsDueCurrent
46000
CY2017Q4 bioc Capital Leases Maintenance And Sales Tax Obligation Payments Due
CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsDue
309000
CY2016Q1 us-gaap Cash
Cash
4572750
CY2016Q2 us-gaap Cash
Cash
3751570
CY2016Q3 us-gaap Cash
Cash
678855
CY2016Q1 us-gaap Assets
Assets
6780830
CY2016Q2 us-gaap Assets
Assets
6303153
CY2016Q3 us-gaap Assets
Assets
3282549
CY2016Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3132372
CY2016Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3134593
CY2016Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2793258
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2526113
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
-489231
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
-419402
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
716279
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
600613
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
668399
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1487224
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1517664
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1918543
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1636994
CY2016Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1304899
CY2016Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1291709
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1278455
CY2016Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1179167
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4773620
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4532363
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4626619
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4092435
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-4875198
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-4594174
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-4743076
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-4186874
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6566992
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7702286
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8370691
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15620049
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6566992
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7702286
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8370691
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15620049
CY2017Q1 us-gaap Cash
Cash
14042388
CY2017Q2 us-gaap Cash
Cash
10000155
CY2017Q3 us-gaap Cash
Cash
5879025
CY2017Q1 us-gaap Assets
Assets
17933413
CY2017Q2 us-gaap Assets
Assets
14653193
CY2017Q3 us-gaap Assets
Assets
11120215
CY2017Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2062544
CY2017Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1561520
CY2017Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1255939
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1421527
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
10418069
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
7342257
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
4026079
CY2017Q1 us-gaap Revenues
Revenues
1683065
CY2017Q2 us-gaap Revenues
Revenues
1278961
CY2017Q3 us-gaap Revenues
Revenues
1111411
CY2017Q4 us-gaap Revenues
Revenues
995226
CY2017Q1 us-gaap Cost Of Revenue
CostOfRevenue
2129454
CY2017Q2 us-gaap Cost Of Revenue
CostOfRevenue
2368705
CY2017Q3 us-gaap Cost Of Revenue
CostOfRevenue
2487054
CY2017Q4 us-gaap Cost Of Revenue
CostOfRevenue
2359909
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
757258
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
841991
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
856698
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
908800
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1906635
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1798026
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1834771
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1650097
CY2017Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1278311
CY2017Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1746867
CY2017Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1675852
CY2017Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1642941
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4388593
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29605953
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31489993
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5476628
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5742964
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5566521
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4432707
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-5693151
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-5821306
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-5666573
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20969131
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26778549
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29605953
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31489993
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20969131
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26778549

Files In Submission

Name View Source Status
0001564590-18-006985-index-headers.html Edgar Link pending
0001564590-18-006985-index.html Edgar Link pending
0001564590-18-006985.txt Edgar Link pending
0001564590-18-006985-xbrl.zip Edgar Link pending
bioc-10k_20171231.htm Edgar Link pending
bioc-20171231.xml Edgar Link completed
bioc-20171231.xsd Edgar Link pending
bioc-20171231_cal.xml Edgar Link unprocessable
bioc-20171231_def.xml Edgar Link unprocessable
bioc-20171231_lab.xml Edgar Link unprocessable
bioc-20171231_pre.xml Edgar Link unprocessable
bioc-ex311_10.htm Edgar Link pending
bioc-ex312_8.htm Edgar Link pending
bioc-ex321_7.htm Edgar Link pending
bioc-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending